Company Profile

Virvio is a pre-clinical biotherapeutic discovery company specializing in computationally designed protein scaffolds called "mini-binders". Mini-binders are small structured proteins designed completely de novo to meet the requirements of the molecular target and indication. The firm's platform generates mini-binder leads having antibody-like affinity and specificity yet also possessing the hyper-stability and manufacturability of small-molecule drugs. The firm is focused on HB36.6, a computationally designed protein with pre- and post-exposure efficacy against influenza. Flu vaccines are only 50-65% effective and current antivirals incur high resistance rates and have low efficacy.